NCT03629223View on ClinicalTrials.gov

Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib

PHASE1CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

August 23, 2018

Primary Completion Date

January 25, 2019

Study Completion Date

January 25, 2019

Conditions
Healthy
Interventions
DRUG

Tepotinib TF2

Participants received a single oral dose of 500 mg Tepotinib TF2 under fasting or fed conditions in treatment period 1 or 2.

DRUG

Tepotinib TF3

Participants received single oral dose of 500 mg (2 x 250 mg)Tepotinib TF3 under fasting or fed conditions in treatment period 1 or 2.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03629223 - Bioequivalence of TF3 and TF2 and Effect of Food on the PK of Tepotinib | Biotech Hunter | Biotech Hunter